Who is sponsoring NCT06667154?

NCT06667154 is sponsored by Aline Fusco Fares, MD.

What drugs are being tested in NCT06667154?

Interventions in NCT06667154: Low-dose nivolumab combined with platinum-based doublet chemotherapy.

What condition does NCT06667154 study?

NCT06667154 studies Lung Cancer, Nonsmall Cell, Non-Small Cell Lung Cancer NSCLC.

Is NCT06667154 still recruiting?

NCT06667154 is currently recruiting now. Last updated 31 October 2024.

Last reviewed 2024-10-31 · How we verify

NCT06667154

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

Recruiting now Phase 2 Last updated 31 October 2024

What this trial tests

Phase 2 trial testing Low-dose nivolumab combined with platinum-based doublet chemotherapy in Lung Cancer, Nonsmall Cell in 33 participants. Currently enrolling.

Timeline

10 October 2023

Primary endpoint
31 October 2025

31 October 2027

Quick facts

Lead sponsor	Aline Fusco Fares, MD
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	10 October 2023
Primary completion	31 October 2025
Estimated completion	31 October 2027
Sites	1 location across Brazil

Drugs / interventions tested

Low-dose nivolumab combined with platinum-based doublet chemotherapy — full drug profile →

Conditions studied

Lung Cancer, Nonsmall Cell — all drugs for Lung Cancer, Nonsmall Cell →
Non-Small Cell Lung Cancer NSCLC — all drugs for Non-Small Cell Lung Cancer NSCLC →

Sponsor

Aline Fusco Fares, MD — full company profile →

Who can join

18 and older, any sex, with Lung Cancer, Nonsmall Cell or Non-Small Cell Lung Cancer NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer, Nonsmall Cell

Currently open trials in the same condition.

NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06426511 — ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC · Phase 2 · recruiting
NCT05384873 — Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer · NA · recruiting
NCT05537922 — I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy · recruiting
NCT05085028 — A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Pat · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06667154 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aline Fusco Fares, MD
Last refreshed: 31 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06667154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing